COPD

Gyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, Idiopathic pulmonary fibrosis, Common, Chronic obstructive pulmonary disease, Safety, Republic, Food, Ocean gyre, IPF, Research, IND, NASH, Pulmonary fibrosis, Patient, CHB, Quarter, Toxicity, Marketing, Clinical trial, Fatty liver disease, Therapy, GAAP, SAN, Orthostatic hypertension, COPD, Pharmaceutical industry

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • In October 2023, Gyre Pharmaceuticals completed enrollment of its Phase 3 trial in patients with CHB-associated liver fibrosis in the PRC.
  • Gyre expects to file an investigational new drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) by the end of 2024.
  • Financial Results for the Quarter Ended March 31, 2024
    Revenues: For the three months ended March 31, 2024, revenues were $27.2 million as a result of Gyre’s indirect controlling interest in Gyre Pharmaceuticals.
  • Use of Non-GAAP Financial Measures by Gyre Therapeutics, Inc.
    Gyre reports financial results in accordance with accounting principles generally accepted in the United States (“GAAP”).

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
FDA, International Society, Inflammation, Bromide, EDT, Chronic obstructive pulmonary disease, Risk, Safety, Food, Conference call, Research, Conference, Information technology, Disease, PDUFA, Patient, Pharming, Marketing, VRNA, Pharmacoeconomics, Growth, BST, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date for Ensifentrine of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.
  • If approved, the Company intends to launch ensifentrine in the US market in the third quarter of 2024.
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, May 9, 2024, to discuss the first quarter 2024 financial results and the corporate update.
  • An electronic copy of the first quarter 2024 results press release will also be made available today on the Company’s website.

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

Retrieved on: 
Giovedì, Maggio 9, 2024
Oaktree Capital Management, Sale, FDA, Sullivan & Cromwell, Oliver Cromwell, Chronic obstructive pulmonary disease, Creditor, Morgan Stanley, Patient, OMERS, VPI, Pharming, VRNA, Growth, Latham & Watkins, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree Capital Management, L.P. (“Oaktree”) and OMERS Life Sciences (“OMERS”).

Key Points: 
  • LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (“VPI” and together with Verona Pharma, the “Company”), have entered into strategic financing agreements providing access to up to $650 million from funds managed by Oaktree Capital Management, L.P. (“Oaktree”) and OMERS Life Sciences (“OMERS”).
  • The agreements provide non-dilutive capital and additional financial flexibility ahead of Verona Pharma’s planned US launch of ensifentrine and will support the Company’s continued growth.
  • The debt facility replaces the existing facility of up to $400 million with funds managed by Oxford Finance LLC and Hercules Capital, Inc. (NYSE: HTGC).
  • This strategic agreement, with access to up to $650 million, allows us to further strengthen our cash position and improve our financial flexibility,” said David Zaccardelli, Pharm.

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Giovedì, Maggio 9, 2024
Chicago Medical School, Sale, University, Patient, Rutgers University, ATS, Alopecia areata, Kinetics, Skin, European Patent Convention, Research, MD, Doctor of Philosophy, Conference, KOL, Potential, ADS, Week, Patent, Data, Dupilumab, University of Rochester, Translational medicine, International Examiner, Magnetic resonance, Atopic dermatitis, Harvard Medical School, ASLN, TREK, Clutch (eggs), Interim, Biology, American Thoracic Society, Associate, Emergency medicine, EPO, SAN, COPD, Pharmaceutical industry

SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.

Key Points: 
  • SAN MATEO, Calif. and SINGAPORE, May 09, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate activities.
  • Research and development expenses were $5.9 million for the first quarter of 2024 compared to $14.1 million for the first quarter of 2023.
  • General and administrative expenses were $3.4 million for the first quarter of 2024 compared to $4.0 million for the first quarter of 2023.
  • Net loss attributable to stockholders for the first quarter of 2024 was $9.9 million compared to a net loss of $19.1 million for the first quarter of 2023.

Polarean’s Xenon MRI to be Featured at Upcoming ATS 2024 Conference

Retrieved on: 
Mercoledì, Maggio 8, 2024
Hypoxemia, Supplement, Pulmonology, Patient, Adolescence, Inhalation, ATS, Euphoria, Adrenal insufficiency, Cystic fibrosis, Dizziness, AIM, Oxygen saturation (medicine), Doctor of Philosophy, Conference, Research, Bronchopulmonary dysplasia, Radiation-induced lung injury, Heart rate, Ageing, Transience, Headache, RIS, MRI, Magnetic resonance imaging, Hypoesthesia, Government, Asthma, Risk, COVID-19, Orthostatic hypertension, COPD, Medical imaging

The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.

Key Points: 
  • The summit is scheduled to take place on May 17th-18th in San Diego, CA, at the Manchester Grand Hyatt San Diego.
  • The Respiratory Innovation Summit, a premier event in the field of pulmonary medicine, unites innovators, investors, clinicians, and advocacy groups.
  • After the dynamic discussions of the Respiratory Innovation Summit, Polarean eagerly anticipates further collaboration within the pulmonary medicine community at the 2024 ATS International Conference, held from May 19th to 22nd.
  • Christopher von Jako, PhD, CEO of Polarean, said: “The Respiratory Innovation Summit and the ATS annual conference serve as invaluable venues to spotlight our Xenon MRI platform, especially to those enthusiastic about fostering collaborative partnerships.

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Retrieved on: 
Lunedì, Maggio 6, 2024
FDA, QIDP, Fast Track, Safety, Infection, Woman, Food, Prevalence, Bacteria, Cough, Water, NTM, Environment, MAC, Patient, Doctor of Pharmacy, Fatigue, Bronchiectasis, Medicine, Soil, MannKind Corporation, Mycobacterium avium complex, Asthma, COPD, Pharmaceutical industry

Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need.

Key Points: 
  • Fast track designation is intended to facilitate the development, and expedite the review, of medicines to treat serious conditions and fill an unmet medical need.
  • “We are pleased with the FDA’s decision to grant Fast Track designation for Clofazimine Inhalation Suspension, providing us an opportunity to accelerate our efforts to potentially bring an important medicine to patients living with NTM,” said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation.
  • The U.S. FDA previously designated Clofazimine Inhalation Suspension as both an orphan drug and a qualified infectious disease product (QIDP) for the treatment of pulmonary NTM infections.
  • NTM lung disease is more common in women over the age of 65, with a predominance in those of Caucasian and Asian descent.

Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare Conference

Retrieved on: 
Lunedì, Maggio 6, 2024
News, Conference, Apsis, Bank, Atopic dermatitis, Therapy, Asthma, SAN, COPD

SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 3:40 p.m. P.T.

Key Points: 
  • SAN FRANCISCO and WALTHAM, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, COPD, asthma and other inflammatory and immunology indications, today announced that Michael Henderson, M.D., Chief Executive Officer and Jane Pritchett Henderson, Chief Financial Officer, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 3:40 p.m. P.T.
  • / 6:40 p.m. E.T.
  • A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

Global Nebulizers Research Report 2024: Market to Reach $2.5 Billion by 2032 - Product Type, Portability, End-User, Application Analysis - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Maggio 9, 2024
Medical Devices, Health, Hospital, Prognosis, Tobacco, Cystic fibrosis, Incidence, Asthma, Organization, COPD, Pharmaceutical industry

The "Global Nebulizers Market Report by Product Type, Portability, End-User, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Nebulizers Market Report by Product Type, Portability, End-User, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The global nebulizers market is witnessing an impressive growth trajectory, with projections indicating a market value of US$ 2.5 Billion by the year 2032.
  • The global nebulizers market report meticulously segments the market by product type, portability, end-user, and application, presenting an in-depth analysis of each sector and its projected growth.
  • The global nebulizers market is on a steady growth path and encapsulates significant opportunities across varied sectors.

New report outlines health impact of air pollution from MidAmerican Energy coal plants in Siouxland

Retrieved on: 
Martedì, Maggio 7, 2024
Education, Organization, University, Public, Physicians for Social Responsibility, MPA, Organic compound, MidAmerican Energy Company, Environmental Health (journal), Chronic obstructive pulmonary disease, Lung cancer, SO2, IEC, Health, Heart, Volatile organic compound, American Lung Association, Partnership, Electricity, Doctor of Philosophy, Employment, Nitrogen, Plant, Public policy, Council, Social responsibility, Sulfur dioxide, Poverty, NOx, Mercury, Multimedia, Air pollution, University of Iowa, Asthma, Winnebago Tribe of Nebraska, COPD

DES MOINES, Iowa, May 7, 2024 /PRNewswire/ -- A new report from the Iowa Environmental Council, released on World Asthma Day, examines the relationship between pollution from coal plants and lung disease in Woodbury County.

Key Points: 
  • Written in partnership with public health experts from organizations including the American Lung Association, Physicians for Social Responsibility, and the Winnebago Tribe of Nebraska's Winnebago Comprehensive Healthcare System, Coal in Siouxland: MidAmerican Energy's Legacy of Air Pollution and Health Impacts highlights how two coal-fired power plants in northwest Iowa operated by MidAmerican Energy harm the health of Siouxland, the multi-state, three county region surrounding Sioux City, IA.
  • "Pollution from coal plants makes our communities sicker and drives worse health outcomes, especially for communities of color and Iowans of low-income."
  • "Emissions from coal plants pose a serious threat to public health in Iowa," says John Rachow, MD, PhD, Past President of Physicians for Social Responsibility.
  • "The data in this report raise troubling questions for us and should be concerning to all Iowans and to MidAmerican Energy," says Smith.

AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024

Retrieved on: 
Mercoledì, Maggio 1, 2024
AMGN, MPA, Effectiveness, Political moderate, Prednisone, ATS, Chronic obstructive pulmonary disease, Emphysema, Polyp (medicine), Inflammation, Hospital, Exercise, ANCA, Post hoc analysis, Abstract, PDT, Research and development, Biomarker, Initiation, Conference, Development, Literature, Vasculitis, History, GPA, Clinical, Amgen, Bronchitis, COPD, Pharmaceutical industry

THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.

Key Points: 
  • THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new respiratory data at the American Thoracic Society (ATS) 2024 International Conference taking place May 12-22 in San Diego.
  • Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.
  • "Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options."
  • Data from the COURSE trial will be presented within the Clinical Trials Symposium.